Retroviral-mediated gene transfer of the IL-4 gene into experimental gliomas can cause tumor rejection, supporting the clinical use of this form of gene therapy for glioblastomas (GBM). In a clinical setting, the administration of dexamethasone (dex) is a standard procedure for GBM patients. This led us to examine the effects of dex on IL-4 gene therapy. We injected intracranially Fischer 344 rats with phosphatebuffered saline, 9L gliosarcoma cells mixed with E86.L4SN
Glucocorticosteroids (GC) play an important role in the management of malignant brain tumors, either primary or secondary and perioperatively in brain surgery.
1 Dexamethasone (dex) is the GC given in the majority of neuro-oncologic patients, at an empirically chosen dosage of 4 mg qid. Dex has a dramatic effect on symptoms in patients with brain tumors by decreasing the blood-tumor barrier permeability and the regional cerebral blood volume.
2 Furthermore, dex may decrease brain-tumor-associated edema by counteracting the action of VEGF. 3 Steroid medications, including dex, also have immunosuppressive functions. Studies based on flow cytometry to quantify the extent of inflammatory cell infiltration in the immunogenic rat C6 glioma model showed that a 7-day course of dex (100 mg/kg/day) resulted in a greater than 50% inhibition of microglia and lymphocyte (but not macrophage) infiltration into tumors. 4 Dex may specifically inhibit the action of IL-4 by decreasing the expression of the IL-4 receptor alpha. 5 These findings should be considered when experimental immunotherapeutic strategies are evaluated for clinical application. We and others previously found that viral-mediated transfer of the interleukin-4 (IL-4) gene may significantly inhibit the growth of C6, 9L and GL261 experimental gliomas. [6] [7] [8] [9] [10] [11] In these experiments IL-4 gene transfer was associated with tumor infiltration by inflammatory cells and particularly T-lymphocytes and macrophages. Thus, in view of future clinical trials based on IL-4 gene transfer in gliomas we have evaluated the effects of dex administration on IL-4 gene therapy of 9L malignant gliomas.
In experiment A, we tested the effects of 250 mg/kg/ day of dex administered for 4 weeks on the growth of 9L gliosarcomas mixed with IL-4 retroviral producer cells (RPC). Results are shown in Figure 1a . This amount, however, was severely toxic. All the rats treated by dex (including those only injected with phosphate-buffered saline, PBS) lost weight and eventually died by day 40. By that time rats injected with 9L and control RPC also died while 5/6 rats injected with 9L cells and IL-4 RPC survived to day 90.
In experiment B, we therefore decreased the amount of dex to 100 mg/kg/day for 2 weeks ( Figure 1b ). This concentration was well tolerated and all rats treated by dex and injected with PBS survived for at least 2 months (an arbitrary endpoint). Rats injected with 9L cells and control RPC, with or without dex, all died by day 40, without significant differences between the two groups. In case of rats bearing IL-4 RPC, however, the difference was quite dramatic. Sixty days after tumor injection, only 1/6 rats treated by dex were alive while 5/6 rats were alive in the group without dex.
In experiment C, we lowered the amount of dex used to 50 mg/kg/day (Figure 1c) . Rats sham-injected with PBS and treated with dex did not show any abnormality until the end of the experiment (60 days). Rats bearing 9L gliosarcomas that were co-injected with control RPC (SBA cells) all died by day 47, independent of dex treatment. Rats with 9L-SBA-dex survived 36 7 10 days, rats with 9L-SBA without dex 34 7 10 days, but the difference was not significant. The rats injected with 9L cells and IL-4 RPC were healthy and all survived until the end of the experiment. However only 50% of the rats injected with 9L and IL-4 RPC and treated with dex survived to day 60.
Levels of dex were measured in the serum of IL-4-treated, control and naïve rats 1 and 2 weeks after the implantation of the osmotic pumps. The data are presented in Table 1 . Each value in the table, except for naïve rats, is representative of one single animal. Blood samples at day 7 and 14 were taken from different animals. Overall, the results show a correlation between the amount of dex administered and blood measurements. Group A, treated by 250 mg/kg/day of dex, had 31.5 7 6.5 ng/ml. Group B (100 mg/kg/day) had 19.0 7 4.0 ng/ml. Group C (50 mg/kg/day) had 10.0 7 1.8 ng/ml (n¼6) of dex in the serum. Differences between dex levels at 7 and 14 days or between different treatments were not significant.
The results we have obtained by administering dex to rats with 9L experimental gliomas show that this steroid, by itself, does not significantly modify the lethality of the tumor. IL-4 gene transfer, on the contrary, has a relevant inhibitory effect on such experimental glioma, confirming previous data. Dex administration in IL-4-treated rats, however, significantly decreases the antiglioma effect of IL-4. This observation may suggest that dex inhibits the T-lymphocyte and macrophage infiltration at the tumor site that is triggered by the presence of IL-4 in the tumor environment. The histological examination of few IL-4 treated tumors, with and without dex appeared to support this explanation. To test this further, we performed another experiment with three groups of rats: one group (n¼10) was injected with 9L cells mixed with control RPC (SBA cells); a second group (n¼9) was injected with 9L cells mixed with IL-4 RPC; and a third ). Three sets of experiments were performed to test the effects of different amounts of dex on the anti-glioma effect of IL-4. In the first experiment (experiment A) we set pumps to release 250 mg/kg/day of dex for 4 weeks. Thirty-eight rats were studied in this experiment, divided into five groups as in A and B: group 1 (n¼3); group 2 (n¼12); group 3 (n¼11); group 4 (n¼6); group 5 (n¼6). In the second experiment (experiment B) osmotic pumps were set to release 100 mg/kg/day of dex for 2 weeks. Twenty-six rats were used in experiment B and divided into five groups with the same characteristics of experiment A (except that dex, when used, was twice the amount used in A): group 1 (n¼3); group 2 (n¼6); group 3 (n¼6); group 4 (n¼6); and group 5 (n¼5). In the third experiment (experiment C) osmotic pumps were set to release 50 mg/kg/day of dex. Twenty-seven rats were studied and divided into five groups: group 1 (n¼3) received an i.c. injection of PBS and dex, to test the toxicity of the drug; group 2 (n¼6) was injected with 9L cells mixed with E86.L4SN 200 cells with dex; group 3 (n¼6) was injected with 9L cells mixed with control SBA cells with dex; group 4 (n¼6) was like group 2 but without dex; group 5 (n¼6) was like group 3 but without dex. Kaplan-Meier analysis was used to evaluate survival using software StatView 4.5 (Abacus, Berkeley, CA, USA).
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Dexamethasone inhibits IL-4 action on gliomas S Benedetti et al group injected with 9L and IL-4 RPC cells was also bearing osmotic pumps releasing 50 mg/kg/day of dex for 14 days (n¼9). All the animals were killed on day 14 after tumor injection. Day 14 was selected because it is around that time that the fate of IL-4-treated and untreated tumors begins to diverge. 8, 12 The presence of macrophages and endothelial cells was tested by lectin staining.
13 CD4+ and CD8+ T-lymphocytes were identified with specific antibodies. Figure 2 gives an overview of the results. IL-4-treated tumors, with and without dex, were smaller than controls. Tumors with dex/IL-4 were the smallest, possibly because of the anti-angiogenic effect of dexamethazone 14, 15 that, in this experimental setting, is delivered when the tumor is not yet established. A great number of necrotic areas, often surrounded by macrophages, was exclusively present in IL-4-treated rats without dex (Figure 2a-d) . Infiltration by CD8+ Tlymphocytes was clear in IL-4-treated rats, scarce in controls and absent in IL-4/dex rats (Figures 2e and f) . CD4+ T-lymphocytes were weakly present only in IL-4-treated rats (Figures 2g and h) . The vessel density was decreased in IL-4-treated rats, particularly in those treated by dex (Figure 2i-l) .
Reports on the anti-angiogenic role of IL-4 are somewhat contradictory. 16, 17 A specific anti-angiogenic action was demonstrated in C6 glioblastomas 18 and our results in 9L tumors confirm this observation. However, in the presence of dex, when immune responses are weakened while the anti-angiogenic action is maintained, the intracranial growth of the tumor increases, supporting the notion that the immune system is playing a major role in the therapeutic action of IL-4. Thus, biologically, our findings confirm that the anti-tumor action of IL-4 is mostly immune-mediated. Other potential inhibitory actions based on anti-proliferative 19 effects of IL-4 in gliomas may be relevant but were not evaluated here. Clinically, the results clearly suggest that immuno-gene therapy strategies for gliomas should be performed when low levels of dex are administered to the patients or, even better, when the clinical situation allows one to avoid its use. Blood samples were drawn from rats in experiments A-C to determine dex levels in the serum 1 and 2 weeks after implantation of the pump. Analysis of dex was performed with an API 3000 triple quadrupole instrument (Applied Biosystems Sciex, Thornhill, Ontario, Canada), interfaced with two Series 200 micro LC pumps (Perkin-Elmer, Norwalk, CT, USA) through a standard Heated Nebulizer source. HPLC conditions were as follows: column: Chromspher C 18, 5 mm, 3 Â 100 mm (Chrompack, Middelburg, Netherlands); flow: 0.5 ml/min; eluent A: 10 mM ammonium formate in water; eluent B: methanol; gradient: from 35% B to 100% B in 8 min; loop 20 ml. The HPLC effluent was directly connected to the ion source. MS conditions were as follows: source: Heated Nebulizer, in negative ion mode and with heater gas at 4001C; orifice voltage: À60 V; ring voltage: À180 V; collision cell gas: nitrogen at a pressure of 2.6 Â 10 À5 torr; collision energy: 30 eV. Quantitative analysis of dex was done by Multiple Reaction Monitoring (MRM), measuring the fragmentation product (m/ z 307) of the deprotonated pseudo-molecular ion (m/z 361). Flumethasone was used as internal standard, by measuring the corresponding MRM transition (m/z 379 -305). Calibration curves (typical rX0.990) were obtained by injecting standard solutions containing variable amounts of dex (1-40 ng/ml) and a fixed amount of flumethasone (20 ng/ml).Serum samples (0.05 ml) were spiked with 1 ng of flumethasone in 0.15 ml of ethanol, vortexed and centrifuged at 3000 rpm for 10 min. An aliquot of the supernatants (0.08 ml) was diluted with water (0.14 ml) and transferred to the HPLC autosampler vials (Perkin-Elmer Series 200) for HPLC-MS/ MS injections For histological analysis rat brains were fixed in Carnoy and embedded in paraffin. Tissue sections were cut at 2 mm on a microtome and stained for histological examination. Hematoxylin and eosin staining was used for routine histological examination. For immunohistological and histochemical evaluations, deparaffined slides which underwent unmasking with buffer citrate (5 mM, pH 6) at 1001C for 6 min were rinsed in PBS-Triton 100 0.3% and incubated with 10% normal goat serum in PBS. Macrophages and blood vessels were stained using biotin-labelled BS-I isolectin B4 (Sigma, 1:50) while CD8 and CD4 T-lymphocyte subsets were stained using a mouse anti-CD8 (Cedarlane, 1:400) and a mouse anti-CD4 (Cedarlane, 1:400) antibodies revealed using biotin-labelled secondary anti-mouse antibody (Vector).
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